Obesity has long been treated as a metabolic problem, a matter of cardiovascular strain and creeping type 2 diabetes. But a growing body of evidence points somewhere more unsettling: the same chronic inflammation, insulin resistance, and oxidative stress that damage the heart and pancreas also erode the synapses that hold memory and cognition together. Now, a comprehensive review published in Frontiers in Synaptic Neuroscience argues that one of the most unexpected allies in decoding this brain–body breakdown is a small, striped tropical fish. The zebrafish, Danio rerio, the review contends, offers a uniquely powerful translational platform for studying how obesity dismantles synaptic function—and for screening peptide-based drugs that might repair the damage.
The logic is compelling. Studying synaptic dynamics in response to systemic metabolic change is notoriously difficult in traditional mammalian models: experiments are expensive, slow, and hard to visualize in real time. Zebrafish sidestep these constraints. Their embryos develop outside the mother’s body, their larvae are optically transparent, and their generation time is short, making large-scale genetic modification and high-throughput screening feasible in ways rodents never were. A bibliometric analysis cited in the review identified more than 93,000 studies involving zebrafish, roughly 20,000 of them relevant to toxicological research—a sign of how deeply this model has penetrated global science. Critically, zebrafish share substantial similarity with the human genome, particularly in the signaling pathways responsible for cellular transduction, and they possess the same metabolic organs as humans, reflecting parallels in energy homeostasis, lipid storage, insulin secretion, and feeding behavior.
When obesity is induced in zebrafish—either through transgenic lines carrying obesogenic genes or through high-fat diets and overfeeding with live prey such as Artemia salina—the resulting disorders closely mirror the human condition. Genetic knockouts of leptin receptor genes like lepa produce marked hyperphagia and automatic adipose accumulation, while diet-induced obesity paradigms replicate the polygenic and environmental complexity of human metabolic syndrome, including systemic lipid shifts and severe hepatic steatosis. Together, these dual modeling strategies establish a reliable experimental baseline for investigating downstream neurobiological comorbidities, such as blood–brain barrier disruption and localized synaptic dysfunction. Fluorescent reporter lines allow researchers to monitor obesity progression in transgenic animals from development onward, supporting longitudinal in vivo studies that would be impractical in opaque mammals.
The review then dissects the pathophysiology of obesity-induced synaptic dysfunction, identifying three converging pillars: hormonal dysregulation, chronic inflammation, and oxidative stress. Insulin and leptin, two peptide hormones that regulate peripheral energy homeostasis, also act as essential neuromodulators in the brain. Insulin crosses the blood–brain barrier and its receptors are abundantly expressed in the hippocampus and prefrontal cortex, where insulin signaling modulates long-term potentiation and long-term depression—the cellular foundations of learning and memory. Leptin, produced by adipocytes, signals energy reserves to the hypothalamus while also exerting direct effects on synaptic structure in the hippocampus. When obesity drives resistance to these hormones—elevated bloodstream levels without corresponding cellular response—synaptic plasticity, neurogenesis, and cognitive function all deteriorate, while increased food intake perpetuates the cycle.
At the molecular level, the review traces conserved signaling cascades. In zebrafish models of diet-induced obesity, excessive lipid intake reduces expression of the Nrf2 pathway in the telencephalon, downregulating key antioxidant genes such as sod1 and catalase. Impaired antioxidant defenses allow reactive oxygen species to accumulate, damaging lipids, proteins, and DNA, and compromising synaptic integrity. In parallel, obesity activates the TLR4/NF-κB inflammatory axis: saturated fatty acids and systemic inflammatory mediators trigger NF-κB nuclear translocation, increasing pro-inflammatory cytokines such as IL-1β and IL-6. Stress-responsive MAPK pathways, particularly p38 MAPK and JNK, are activated by oxidative and inflammatory stimuli and implicated in neuronal damage. The high degree of conservation of these pathways in zebrafish underscores the model’s utility for investigating molecular mechanisms of obesity-induced neurodegeneration.
The blood–brain barrier emerges as a critical casualty. High-fat diet exposure downregulates tight junction proteins including claudin-5 and occludin, increasing barrier permeability and allowing peripheral inflammatory signaling to invade the brain. Comparable effects have been reported in zebrafish models of diet-induced obesity, with increased oxidative stress, BBB leakage, and neuroinflammatory responses observed. Once inside, these mediators activate glial cells—astrocytes and microglia—initiating neuroinflammation. Chronic microglial activation drives a shift from a neuroprotective M2 state to a pro-inflammatory M1 state, releasing ROS and cytokines that impair neurogenesis, long-term potentiation, and synaptic integrity. Zebrafish larvae allow real-time visualization of microglial activation, cell migration, and neuroimmune interactions using advanced imaging, while individual neurons and synapses can be traced in both larvae and adults.
Glial cells themselves undergo a Warburg-like metabolic reprogramming under obesity, shifting toward aerobic glycolysis and away from mitochondrial oxidative metabolism. This process, mediated by upregulation of HIF-1α and GLUT1, increases glycolytic flux and intracellular accumulation of lactate and ROS, which activate the NLRP3 inflammasome. Upon assembly, the inflammasome activates caspase-1, driving maturation and secretion of IL-1β and IL-18—central mediators of obesity-associated neuroinflammation. These metabolic byproducts also impair the astrocyte–neuron lactate shuttle, reducing metabolic support to neurons and leading to ATP depletion and structural instability. Astrocytes, which supply cholesterol to neurons through Apolipoprotein E, become dysregulated; the APOE4 variant, a known Alzheimer’s risk factor, alters brain lipid metabolism, reducing available cholesterol and leading to loss of synaptic vesicles and decreased SNAP-25 protein, compromising hippocampal plasticity in vivo.
The gut–brain axis adds another dimension. Obesity-associated dysbiosis promotes intestinal inflammation, systemic metabolic dysfunction, and ultimately neuroinflammation. Microbial metabolites, including short-chain fatty acids, stimulate secretion of insulin, ghrelin, leptin, and amylin, while the microbiota produces neurotransmitters and neuromodulators including catecholamines, GABA, and tryptophan-derived metabolites. Under inflammatory conditions, tryptophan metabolism can be redirected toward quinolinic acid, a neurotoxic metabolite associated with neuronal death. Molecular mimicry adds a further layer: bacterial amyloids such as the Curli protein from Escherichia coli are structurally analogous to human Aβ and α-synuclein and can trigger exaggerated immune responses, accelerating protein aggregation linked to neurodegeneration. Zebrafish, with their capacity for gnotobiotic models created through rapid, low-cost surface sterilization of eggs, allow researchers to correlate the direct function of specific microbial components with brain health—an advancement difficult to achieve in more complex models.
On the therapeutic front, the review highlights emerging peptide-based interventions. Liraglutide, a GLP-1 receptor agonist, promotes neuronal viability and regulates neuroinflammatory processes; upon binding GLP-1 receptors, it activates PI3K/Akt and MAPK/ERK signaling cascades that contribute to neuronal survival, attenuation of excitotoxicity, and enhancement of antioxidant defenses. Short-term liraglutide treatment exerts anxiolytic-like effects in zebrafish, while long-term administration mitigates the behavioral and physiological consequences of chronic unpredictable stress. Tirzepatide, a dual GIP and GLP-1 receptor agonist, improved cognitive performance and restored levels of GSH, catalase, and IL-10 in zebrafish models of diet-induced obesity with type 2 diabetes, effects attributed to antioxidant, anti-inflammatory, anti-apoptotic, and AMPK-activating neuroprotective actions. Beyond hormonal peptides, neurotrophic factors such as BDNF, which activates TrkB receptors and stimulates downstream PI3K/Akt and MAPK pathways, represent promising strategies for counteracting obesity-associated synaptic dysfunction. PACAP38, a highly conserved neuropeptide, protected inner ear hair cells from oxidative stress in zebrafish, mitigating stress-induced apoptosis.
Cutting-edge technologies are accelerating this work. Two-photon microscopy, using infrared light invisible to fish, enables visualization of synapses, dendrites, and entire neuronal populations in vivo with high resolution while minimizing interference with natural behavior. Optogenetics allows precise control of neuronal activity through light-sensitive proteins expressed in specific neurons. Single-cell RNA sequencing maps cellular heterogeneity and transcriptional states, comparing zebrafish Alzheimer’s and Parkinson’s models with human tissues to reveal shared and distinct molecular responses. Artificial intelligence, including machine learning and computer vision, transforms analysis of complex behavioral datasets, discriminating movement disorders and predicting peptide efficacy based on molecular structure and biological target interactions. The review acknowledges real limitations: zebrafish lack a laminated cerebral cortex, their short lifespan complicates temporal scaling to human disease progression, and water immersion administration of peptides in larvae yields unpredictable bioavailability. Yet pharmacokinetic parameters obtained in zebrafish correlate with those observed in mammals, including humans. The review concludes that zebrafish represent a balanced experimental system—more cost-effective than mouse models while retaining greater biological complexity than in vitro approaches—and that their role in the drug discovery pipeline is no longer a distant prospect but a consolidating reality, supporting the transition from molecular discovery to clinically relevant metabolic neurotherapies.
Subject of Research: Neuroscience
Article Title: Zebrafish as a translational model for peptide-mediated synaptic dysfunction related to obesity
Article References: Rodrigues, A. C., Lacerda, A. P., Mukoyama, L. T. H., de Carvalho, G. B., da Mata, J. A. L., Buccini, D. F., Franco, O. L., & Migliolo, L. (2026). Zebrafish as a translational model for peptide-mediated synaptic dysfunction related to obesity. Frontiers in Synaptic Neuroscience, 18, Article 1845252. https://doi.org/10.3389/fnsyn.2026.1845252
Image Credits: AI Generated
DOI: 10.3389/fnsyn.2026.1845252
Keywords: zebrafish, obesity, synaptic dysfunction, neuroinflammation, peptides, GLP-1, BDNF, gut-brain axis, neurodegeneration, translational model, translational, model
Cite Scienmag News
Cassandra Pierce. (October 16, 2026). Transparent Fish, Hidden Damage: Zebrafish Reveal How Obesity Breaks Brain Synapses. Scienmag. https://scienmag.com/transparent-fish-hidden-damage-zebrafish-reveal-how-obesity-breaks-brain-synapses/
Cassandra Pierce. "Transparent Fish, Hidden Damage: Zebrafish Reveal How Obesity Breaks Brain Synapses." Scienmag, 16 October 2026, https://scienmag.com/transparent-fish-hidden-damage-zebrafish-reveal-how-obesity-breaks-brain-synapses/. Accessed 16 October 2026.
Cassandra Pierce. "Transparent Fish, Hidden Damage: Zebrafish Reveal How Obesity Breaks Brain Synapses." Scienmag. October 16, 2026. https://scienmag.com/transparent-fish-hidden-damage-zebrafish-reveal-how-obesity-breaks-brain-synapses/

